Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Opioid utilization by pregnant women with sickle cell disease and the risk of neonatal abstinence syndrome
source: Journal of the National Medical Association
year: 2018
authors: Nnoli A, Seligman NS, Dysart K, Baxter JK, Ballas SK
summary/abstract:BACKGROUND:
Pregnant women with sickle cell disease (SCD) are at increased risk of maternal and fetal complications. There are limited data on the outcome of the treatment of VOCs with opioids in relation to neonatal complications during pregnancy.
METHODS:
This is a retrospective cohort study of women with SCD from January 1999 to December 2008. Women with SCD were identified by ICD-9 codes and matched 2:1 to a control group of women on methadone for opioid dependence. The primary outcome was the rate of neonatal abstinence syndrome (NAS). Secondary outcomes included the mean NAS score prior to treatment and the length of treatment. Statistical analysis was performed using SPSS.
RESULTS:
Twenty-one women with SCD who delivered a total of 23 neonates were included. The rate of NAS among infants born to women with SCD who were treated with opioids at any time was 22% compared to 54% in the methadone controls (p = .010). The rate of NAS was 27% among infants born to women taking opioids daily compared to 54% in the methadone control group (p = .062).
CONCLUSIONS:
Neonates born to women with SCD who are treated with daily opioids are at a similar risk for developing NAS as those born to mothers on methadone for opioid dependence. Neonates born to women with SCD treated with episodic opioids are at a significantly lower risk for developing NAS than those born to women on methadone for opioid dependence.
organization: Jefferson Medical College of Thomas Jefferson University, United States
DOI: 10.1016/j.jnma.2017.04.002
read more
+myBinderRelated Content
-
Methadone provides pain relief for kids with sickle cellMany children with sickle cell disease e...
-
Pediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
-
A Multiyear Cross-Sectional Study of Guideline Adherence for the Timeliness of Opioid Administration in Children Wit...Study objective: The National Heart, Lu...
-
2017 SiNERGe Webinar July 14 – Chronic Opioid Therapy & Sickle Cell Diseasehttps://www.youtube.com/watch?v=8WZNTwPD...
-
Long-term opioids may not be best pain management option for all sickle cell patientsSmall study shows some on opioids report...
-
Sickle cell advocate wins fight for high-dose opioidsGeorge H. Carter appears to have won h...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.